Clinical Trial Update: Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the combination of durvalumab and Vicineum in patients with high-grade non-muscle-invasive bladder cancer previously treated with BCG; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Vicineum

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Urinary Bladder Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2023-10-26